Company
Headquarters: Taizhou, China
Employees: 8,446
CN¥10.21 Billion
CNY as of Jan. 1, 2025
US$1.40 Billion
| Company | Market Cap (USD) |
|---|---|
| Lilly | $689.42 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $487.54 B |
| Johnson & Johnson | $353.05 B |
| AbbVie | $301.60 B |
Zhejiang Hisun Pharmaceutical Co., Ltd. manufactures and supplies pharmaceutical products in China. It provides active pharmaceutical ingredients and finished dosage form products. The company offers products in the areas of anti-tumor, cardiovascular, anti-infective, liver care, orthopedics, anticancer, anti-parasitic, immunosuppressant, etc.; and weight loss, anti-viral, anti-TB, veterinary pharma, and others. It also provides product consultation and CMO/CRO manufacturing services. The company was founded in 1956 and is headquartered in Taizhou, China.
| Last Financial Reports Date | Sept. 30, 2024 |
| Revenue TTM | CN¥9.55 B |
| EBITDA | CN¥1.51 B |
| Gross Profit TTM | CN¥3.70 B |
| Profit Margin | -0.21% |
| Operating Margin | 14.22% |
| Quarterly Revenue Growth | -0.40% |
Zhejiang Hisun Pharmaceutical Co. Ltd has the following listings and related stock indices.
Stock: SSE: 600267 wb_incandescent